Vesicular monoamine transporter 2 and the acute and long-term response to 3,4-(±)-methylenedioxymethamphetamine.

3,4-(±)-Methylenedioxymethamphetamine (MDMA, Ecstasy) is a ring-substituted amphetamine derivative with potent psychostimulant properties. The neuropharmacological effects of MDMA are biphasic in nature, initially causing synaptic monoamine release, primarily of serotonin (5-HT). Conversely, the long-term effects of MDMA manifest as prolonged depletions in 5-HT, and reductions in 5-HT reuptake transporter (SERT), indicative of serotonergic neurotoxicity. MDMA-induced 5-HT efflux relies upon disruption of vesicular monoamine storage, which increases cytosolic 5-HT concentrations available for release via a carrier-mediated mechanism. The vesicular monoamine transporter 2 (VMAT2) is responsible for packaging monoamine neurotransmitters into cytosolic vesicles. Thus, VMAT2 is a molecular target for a number of psychostimulant drugs, including methamphetamine and MDMA. We investigated the effects of depressed VMAT2 activity on the adverse responses to MDMA, via reversible inhibition of the VMAT2 protein with Ro4-1284. A single dose of MDMA (20 mg/kg, subcutaneous) induced significant hyperthermia in rats. Ro4-1284 (10 mg/kg, intraperitoneal) pretreatment prevented the thermogenic effects of MDMA, instead causing a transient decrease in body temperature. MDMA-treated rats exhibited marked increases in horizontal velocity and rearing behavior. In the presence of Ro4-1284, MDMA-mediated horizontal hyperlocomotion was delayed and attenuated, whereas rearing activity was abolished. Finally, Ro4-1284 prevented deficits in 5-HT content in rat cortex and striatum, and reduced depletions in striatal SERT staining, 7 days after MDMA administration. In summary, acute inhibition of VMAT2 by Ro4-1284 protected against MDMA-mediated hyperthermia, hyperactivity, and serotonergic neurotoxicity. The data suggest the involvement of VMAT2 in the thermoregulatory, behavioral, and neurotoxic effects of MDMA.

[1]  Alison I. Bernstein,et al.  The vesicular monoamine transporter 2: An underexplored pharmacological target , 2014, Neurochemistry International.

[2]  T. Monks,et al.  Serotonin reuptake transporter deficiency modulates the acute thermoregulatory and locomotor activity response to 3,4-(±)-methylenedioxymethamphetamine, and attenuates depletions in serotonin levels in SERT-KO rats. , 2014, Toxicological Sciences.

[3]  S. Ho,et al.  LRRK2 R1441G mice are more liable to dopamine depletion and locomotor inactivity , 2014, Annals of clinical and translational neurology.

[4]  G. Miller,et al.  Reduced vesicular storage of catecholamines causes progressive degeneration in the locus ceruleus , 2014, Neuropharmacology.

[5]  L. Dwoskin,et al.  Effects of VMAT2 inhibitors lobeline and GZ‐793A on methamphetamine‐induced changes in dopamine release, metabolism and synthesis in vivo , 2013, Journal of neurochemistry.

[6]  W. Ondo,et al.  Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature. , 2012, Clinical therapeutics.

[7]  Joshua S. Beckmann,et al.  The effect of a novel VMAT2 inhibitor, GZ-793A, on methamphetamine reward in rats , 2011, Psychopharmacology.

[8]  G. Miller,et al.  VMAT2-Deficient Mice Display Nigral and Extranigral Pathology and Motor and Nonmotor Symptoms of Parkinson's Disease , 2011, Parkinson's disease.

[9]  Joshua S. Beckmann,et al.  The Novel Pyrrolidine Nor-Lobelane Analog UKCP-110 [cis-2,5-di-(2-phenethyl)-pyrrolidine hydrochloride] Inhibits VMAT2 Function, Methamphetamine-Evoked Dopamine Release, and Methamphetamine Self-Administration in Rats , 2010, Journal of Pharmacology and Experimental Therapeutics.

[10]  Andreas Meisel,et al.  Molecular and Cellular Mechanisms of Ecstasy-Induced Neurotoxicity: An Overview , 2009, Molecular Neurobiology.

[11]  G. Miller,et al.  Protective Actions of the Vesicular Monoamine Transporter 2 (VMAT2) in Monoaminergic Neurons , 2009, Molecular Neurobiology.

[12]  S. Kato,et al.  Risperidone attenuates and reverses hyperthermia induced by 3,4-methylenedioxymethamphetamine (MDMA) in rats. , 2008, Neurotoxicology.

[13]  P. Emson,et al.  Reduced vesicular storage of dopamine exacerbates methamphetamine‐induced neurodegeneration and astrogliosis , 2008, Journal of neurochemistry.

[14]  U. Dirnagl,et al.  5,7-Dihydroxitryptamine toxicity to serotonergic neurons in serum free raphe cultures. , 2008, European journal of pharmacology.

[15]  Peter M. Gayed.  Neuroscience , 2008, The Yale Journal of Biology and Medicine.

[16]  M. Leist,et al.  Vesicular monoamine transporter 2 regulates the sensitivity of rat dopaminergic neurons to disturbed cytosolic dopamine levels , 2007, Brain Research.

[17]  R. Rodriguiz,et al.  Vmat2 Heterozygous Mutant Mice Display a Depressive-Like Phenotype , 2007, The Journal of Neuroscience.

[18]  Jie Yuan,et al.  Loss of Serotonin Transporter Protein after MDMA and Other Ring-Substituted Amphetamines , 2006, Neuropsychopharmacology.

[19]  Allison G. Dempsey,et al.  Interaction of Amphetamines and Related Compounds at the Vesicular Monoamine Transporter , 2006, Journal of Pharmacology and Experimental Therapeutics.

[20]  Q. D. Walker,et al.  Sex differences in the neurochemical and functional effects of MDMA in Sprague–Dawley rats , 2006, Psychopharmacology.

[21]  B. Yamamoto,et al.  L-Tyrosine Contributes to (+)-3,4-Methylenedioxymethamphetamine-Induced Serotonin Depletions , 2006, The Journal of Neuroscience.

[22]  T. Monks,et al.  Age-dependent (+)MDMA-mediated neurotoxicity in mice. , 2005, Neurotoxicology.

[23]  B. Blough,et al.  N-Substituted Piperazines Abused by Humans Mimic the Molecular Mechanism of 3,4-Methylenedioxymethamphetamine (MDMA, or ‘Ecstasy’) , 2005, Neuropsychopharmacology.

[24]  B. Yamamoto,et al.  Lobeline Attenuates Methamphetamine-Induced Changes in Vesicular Monoamine Transporter 2 Immunoreactivity and Monoamine Depletions in the Striatum , 2005, Journal of Pharmacology and Experimental Therapeutics.

[25]  P. S. Frankel,et al.  Effects of dopamine D1- or D2-like receptor antagonists on the hypermotive and discriminative stimulus effects of (+)-MDMA , 2004, Psychopharmacology.

[26]  G. Rebec,et al.  Acute effects of 3,4-methylenedioxymethamphetamine on striatal single-unit activity and behavior in freely moving rats: differential involvement of dopamine D1 and D2 receptors , 2003, Brain Research.

[27]  M. Colado,et al.  The Pharmacology and Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”) , 2003, Pharmacological Reviews.

[28]  A. Kanthasamy,et al.  Unilateral infusion of a dopamine transporter antisense into the substantia nigra protects against MDMA-induced serotonergic deficits in the ipsilateral striatum , 2002, Neuroscience.

[29]  J. Haycock,et al.  Differential trafficking of the vesicular monoamine transporter-2 by methamphetamine and cocaine. , 2002, European journal of pharmacology.

[30]  R. Rothman,et al.  Therapeutic and adverse actions of serotonin transporter substrates. , 2002, Pharmacology & therapeutics.

[31]  M. Colado,et al.  The pharmacology of the acute hyperthermic response that follows administration of 3,4‐methylenedioxymethamphetamine (MDMA, ‘ecstasy’) to rats , 2002, British journal of pharmacology.

[32]  V. Sánchez,et al.  The mechanisms involved in the long‐lasting neuroprotective effect of fluoxetine against MDMA (‘ecstasy’)‐induced degeneration of 5‐HT nerve endings in rat brain , 2001, British journal of pharmacology.

[33]  S. Parsons.  Transport mechanisms in acetylcholine and monoamine storage , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[34]  K. Rice,et al.  Neurochemical neutralization of amphetamine-type stimulants in rat brain by the indatraline analog (−)-HY038 , 2000, Brain Research Bulletin.

[35]  J. Haycock,et al.  Synaptic Vesicle Transporter Expression Regulates Vesicle Phenotype and Quantal Size , 2000, The Journal of Neuroscience.

[36]  U. McCann,et al.  (±)3,4-Methylenedioxymethamphetamine (‘Ecstasy’)-Induced Serotonin Neurotoxicity: Studies in Animals , 2000, Neuropsychobiology.

[37]  P. Sonsalla,et al.  Inhibition of brain vesicular monoamine transporter (VMAT2) enhances 1-methyl-4-phenylpyridinium neurotoxicity in vivo in rat striata. , 2000, The Journal of pharmacology and experimental therapeutics.

[38]  M. Ramírez,et al.  Alpha-lipoic acid prevents 3,4-methylenedioxy-methamphetamine (MDMA)-induced neurotoxicity. , 1999, Neuroreport.

[39]  M. Starr,et al.  Dual effects of l-3,4-dihydroxyphenylalanine on aromatic l-amino acid decarboxylase, dopamine release and motor stimulation in the reserpine-treated rat: evidence that behaviour is dopamine independent , 1999, Neuroscience.

[40]  S. Butcher,et al.  Behavioural analysis of the acute and chronic effects of MDMA treatment in the rat , 1999, Psychopharmacology.

[41]  R. Gainetdinov,et al.  Increased Methamphetamine Neurotoxicity in Heterozygous Vesicular Monoamine Transporter 2 Knock-Out Mice , 1999, The Journal of Neuroscience.

[42]  S. Yeh.  N‐tert‐butyl‐alpha‐phenylnitrone protects against 3,4‐methylenedioxymethamphetamine‐induced depletion of serotonin in rats , 1999, Synapse.

[43]  D. Mostofsky,et al.  Treatment with a polyunsaturated fatty acid prevents deleterious effects of Ro4-1284. , 1999, European journal of pharmacology.

[44]  L. Seiden,et al.  Reserpine attenuates d-amphetamine and MDMA-induced transmitter release in vivo: a consideration of dose, core temperature and dopamine synthesis , 1998, Brain Research.

[45]  J. del Río,et al.  The role of dopaminergic systems in the perinatal sensitivity to 3, 4-methylenedioxymethamphetamine-induced neurotoxicity in rats. , 1998, The Journal of pharmacology and experimental therapeutics.

[46]  M. Colado,et al.  The relationship between the degree of neurodegeneration of rat brain 5-HT nerve terminals and the dose and frequency of administration of MDMA (`ecstasy') , 1998, Neuropharmacology.

[47]  L. Dwoskin,et al.  Lobeline Displaces [3H]Dihydrotetrabenazine Binding and Releases [3H]Dopamine from Rat Striatal Synaptic Vesicles: Comparison with d‐Amphetamine , 1998, Journal of neurochemistry.

[48]  Fei Xu,et al.  Knockout of the Vesicular Monoamine Transporter 2 Gene Results in Neonatal Death and Supersensitivity to Cocaine and Amphetamine , 1997, Neuron.

[49]  J. Richards,et al.  Methylenedioxymethamphetamine-induced serotonin deficits are followed by partial recovery over a 52-week period. Part I: Synaptosomal uptake and tissue concentrations. , 1996, The Journal of pharmacology and experimental therapeutics.

[50]  G. Gudelsky,et al.  Carrier‐Mediated Release of Serotonin by 3,4‐Methylenedioxymethamphetamine: Implications for Serotonin‐Dopamine Interactions , 1996, Journal of neurochemistry.

[51]  G. Rudnick,et al.  Amphetamine derivatives interact with both plasma membrane and secretory vesicle biogenic amine transporters. , 1993, Molecular pharmacology.

[52]  G. Rudnick,et al.  From synapse to vesicle: the reuptake and storage of biogenic amine neurotransmitters. , 1993, Biochimica et biophysica acta.

[53]  E. Azmitia,et al.  Integrative transporter-mediated release from cytoplasmic and vesicular 5-hydroxytryptamine stores in cultured neurons. , 1993, European journal of pharmacology.

[54]  J. Fitzgerald,et al.  Interactions of methylenedioxymethamphetamine with monoamine transmitter release mechanisms in rat brain slices , 1993, Naunyn-Schmiedeberg's Archives of Pharmacology.

[55]  M. Geyer,et al.  Serotonin release contributes to the locomotor stimulant effects of 3,4-methylenedioxymethamphetamine in rats. , 1990, The Journal of pharmacology and experimental therapeutics.

[56]  C. J. Schmidt,et al.  Antagonism of the neurotoxicity due to a single administration of methylenedioxymethamphetamine. , 1990, European journal of pharmacology.

[57]  S. Peroutka,et al.  Reserpine does not prevent 3,4-methylenedioxymethamphetamine-induced neurotoxicity in the rat , 1989, Neuroscience Letters.

[58]  G. Reynolds,et al.  Depletion of monoamine transmitters by tetrabenazine in brain tissue in Huntington's disease , 1988, Neuropharmacology.

[59]  D. Pettibone,et al.  Tetrabenazine-induced depletion of brain monoamines: characterization and interaction with selected antidepressants. , 1984, European journal of pharmacology.

[60]  B. Brodie,et al.  Persistence of reserpine action after the disappearance of drug from brain: effect on serotonin. , 1956, The Journal of pharmacology and experimental therapeutics.

[61]  Ashish P. Vartak,et al.  The vesicular monoamine transporter-2: an important pharmacological target for the discovery of novel therapeutics to treat methamphetamine abuse. , 2014, Advances in pharmacology.

[62]  Siamak Shahidi,et al.  BRAIN RES BULL , 2008 .

[63]  K. Rice,et al.  Amphetamine‐type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin , 2001, Synapse.

[64]  R. Hen,et al.  Locomotor response to MDMA is attenuated in knockout mice lacking the 5-HT1B receptor , 1999, Psychopharmacology.

[65]  C. J. Schmidt,et al.  Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. , 1987, The Journal of pharmacology and experimental therapeutics.